Nivolumab–ipilimumab — exploiting the mutation burden of NSCLCs

Nivolumab–ipilimumab — exploiting the mutation burden of NSCLCsNivolumab–ipilimumab — exploiting the mutation burden of NSCLCs, Published online: 27 April 2018; doi:10.1038/s41571-018-0034-yNivolumab–ipilimumab — exploiting the mutation burden of NSCLCs

Source: Nature Clinical Practice Oncology - April 27, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research